BioSpace News Archive

Drug Development

FDA Needs More Time to Assess Bluebird Bio Gene Therapy BLAs

The extensions are due to the FDA’s requiring more time to review additional clinical data it had requested from bluebird.

January 18, 2022
·
2 min read
·
Mark Terry
Business

23andMe and GSK Look to Push Collaborative Success Another Year

Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.

January 18, 2022
·
3 min read
·
Alex Keown
Business

Chamath Palihapitiya-Supported SPAC Backs ProKidney in $2.64B Deal

The SPAC announced it is merging with medical technology company ProKidney LP, in a deal that values the combined equity of the companies at $2.64 billion.

January 18, 2022
·
2 min read
·
Alvin Clavines
Policy

Gilead Alleges $250 Million of Counterfeit HIV Drugs Were Sold Over 2 Years

Gilead Sciences reported that about $250 million of counterfeit versions of its HIV drugs, Biktarvy and Descovy, were sold to pharmacies over two years.

January 18, 2022
·
4 min read
·
Mark Terry
Lonza and NNIT to Host Free Webinar on MES for the Future – Achieving Pharma 4.0 through Accelerated MES Implementation

On 25 January, Lonza Bioscience Informatics and NNIT will host a free 60-minute webinar to discuss the key requirements of next generation Manufacturing Execution Systems (MES) and how small- and medium-sized companies can overcome critical implementation challenges for accelerated pharma digitalization.

January 18, 2022
·
5 min read
Drug Development

Early Career Shift Serendipitous for Kinaset CEO Robert Clarke, Asthma Patients

The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.

January 18, 2022
·
4 min read
·
Gail Dutton
Drug Development

Moderna CEO Hints At Possible 3-in-1 COVID-19/Flu/RSV Vaccine by Fall

Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the RSV.

January 18, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Born To Be Wild-Type: Unleashing the Power of Cytokines

Werewolf Therapeutics is designing and developing molecules that unleash the natural ferocity of cytokines for the treatment of cancer.

January 18, 2022
·
6 min read
·
Heather McKenzie
Business

Searching for Medicine’s Answers in the Most Powerful Library on Earth

Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.

January 18, 2022
·
8 min read
·
Heather McKenzie
Deals

Money on the Move: January 12 – 18

Funds are always flowing in the life science industry. Here’s where the money’s headed this week.

January 18, 2022
·
2 min read
·
Kate Goodwin